Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
1998 1
1999 10
2000 4
2001 5
2002 4
2003 7
2004 7
2005 6
2006 7
2007 8
2008 4
2009 4
2010 6
2011 7
2012 12
2013 10
2014 6
2015 12
2016 16
2017 5
2018 8
2019 17
2020 11
2021 14
2022 7
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.
Alfaro-Lara R, Espinosa-Ortega HF, Arce-Salinas CA; PRECIS study group, all physicians belong to Division of Internal Medicine. Hospital Central Sur de Pemex. Alfaro-Lara R, et al. Reumatol Clin (Engl Ed). 2019 May-Jun;15(3):133-139. doi: 10.1016/j.reuma.2017.07.020. Epub 2017 Sep 1. Reumatol Clin (Engl Ed). 2019. PMID: 28867467 Free article. English, Spanish.
OBJECTIVE: To assess the efficacy and side effects of methotrexate and leflunomide in patients with rheumatoid arthritis (RA) as the first disease-modifying antirheumatic drug (DMARD). ...Leflunomide was linked to a greater increase in liver enzymes, but there were …
OBJECTIVE: To assess the efficacy and side effects of methotrexate and leflunomide in patients with rheumatoid arthritis (RA) as the …
Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials.
Golicki D, Newada M, Lis J, Pol K, Hermanowski T, Tłustochowicz M. Golicki D, et al. Pol Arch Med Wewn. 2012;122(1-2):22-32. doi: 10.20452/pamw.1131. Epub 2012 Jan 11. Pol Arch Med Wewn. 2012. PMID: 22353705 Free article. Review.
Efficacy of leflunomide did not differ from that of methotrexate with reference to the majority of endpoints. ...CONCLUSIONS: There were no significant differences between the effects of treatment with leflunomide and methotrexate or sulfasalazine, but leflunomid
Efficacy of leflunomide did not differ from that of methotrexate with reference to the majority of endpoints. ...CONCLUSIONS: There w …
Leflunomide for treating rheumatoid arthritis.
Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, Wells G. Osiri M, et al. Cochrane Database Syst Rev. 2003;2002(1):CD002047. doi: 10.1002/14651858.CD002047. Cochrane Database Syst Rev. 2003. PMID: 12535423 Free PMC article. Review.
Using the ACR20 improvement criteria, there was an absolute difference in improvement of 28% (95% confidence interval: 21 - 35%) favouring leflunomide (232 out of 413 leflunomide treated patients compared to 89 out of 311 placebo patients met the criteria). There wa …
Using the ACR20 improvement criteria, there was an absolute difference in improvement of 28% (95% confidence interval: 21 - 35%) favouring …
Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up.
Fu Q, Wu C, Dai M, Wang S, Xu J, Dai L, Li Z, He L, Zhu X, Sun L, Lu L, Bao C. Fu Q, et al. Ann Rheum Dis. 2022 Nov;81(11):1549-1555. doi: 10.1136/ard-2022-222486. Epub 2022 Jul 4. Ann Rheum Dis. 2022. PMID: 35788493 Free PMC article. Clinical Trial.
Extrarenal flare occurred in two patients from the azathioprine group and one patient from the leflunomide group. The incidence of adverse events was similar in the 2 groups: leflunomide 56.5% and azathioprine 58.9%. ...Leflunomide may provide a new candidate …
Extrarenal flare occurred in two patients from the azathioprine group and one patient from the leflunomide group. The incidence of ad …
Leflunomide in rheumatoid arthritis: recommendations through a process of consensus.
Maddison P, Kiely P, Kirkham B, Lawson T, Moots R, Proudfoot D, Reece R, Scott D, Sword R, Taggart A, Thwaites C, Williams E. Maddison P, et al. Rheumatology (Oxford). 2005 Mar;44(3):280-6. doi: 10.1093/rheumatology/keh500. Epub 2005 Jan 18. Rheumatology (Oxford). 2005. PMID: 15657072 Review.
OBJECTIVES: To determine, by consensus, the optimal use of leflunomide in rheumatoid arthritis (RA), using a multidisciplinary panel of experts and performing meta-analyses of available data. ...In refractory cases, leflunomide may be used in combination with, for e …
OBJECTIVES: To determine, by consensus, the optimal use of leflunomide in rheumatoid arthritis (RA), using a multidisciplinary panel …
The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis.
Cao H, Rao Y, Liu L, Lin J, Yang H, Zhang X, Chen Z. Cao H, et al. PLoS One. 2015 Dec 15;10(12):e0144548. doi: 10.1371/journal.pone.0144548. eCollection 2015. PLoS One. 2015. PMID: 26670616 Free PMC article. Review.
OBJECTIVE: To evaluate the clinical efficacy and safety of leflunomide as a new immunosuppressive medicine in lupus nephritis (LN) through a meta-analysis. ...The SLEDAI score, urine protein level and serum creatinine decreased significantly following leflunomide tr …
OBJECTIVE: To evaluate the clinical efficacy and safety of leflunomide as a new immunosuppressive medicine in lupus nephritis (LN) th …
Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials.
Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Conway R, et al. J Rheumatol. 2016 May;43(5):855-60. doi: 10.3899/jrheum.150674. Epub 2016 Mar 15. J Rheumatol. 2016. PMID: 26980577 Review.
OBJECTIVE: To evaluate the relative risk (RR) of pulmonary disease among patients with rheumatoid arthritis (RA) treated with leflunomide (LEF). METHODS: We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials to April 15, 2014. ...
OBJECTIVE: To evaluate the relative risk (RR) of pulmonary disease among patients with rheumatoid arthritis (RA) treated with leflunomide
Leflunomide treatment for patients hospitalised with COVID-19: DEFEAT-COVID randomised controlled trial.
Kralj-Hans I, Li K, Wesek A, Lamorgese A, Omar F, Ranasinghe K, McGee M, Brack K, Li S, Aggarwal R, Bulle A, Kodre A, Sharma S, Fluck D, John I, Sharma P, Belsey JD, Li L, Seshasai SRK, Li HL, Marczin N, Chen Z; DEFEAT-COVID Investigators. Kralj-Hans I, et al. BMJ Open. 2023 Apr 13;13(4):e068179. doi: 10.1136/bmjopen-2022-068179. BMJ Open. 2023. PMID: 37055207 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the clinical efficacy and safety of leflunomide (L) added to the standard-of-care (SOC) treatment in COVID-19 patients hospitalised with moderate/critical clinical symptoms. ...Incidence of serious AEs was similar between the groups and none was attr …
OBJECTIVE: To evaluate the clinical efficacy and safety of leflunomide (L) added to the standard-of-care (SOC) treatment in COVID-19 …
Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial.
Belani PJ, Kavadichanda CG, Negi VS. Belani PJ, et al. Rheumatol Int. 2022 May;42(5):771-782. doi: 10.1007/s00296-021-04994-1. Epub 2021 Sep 29. Rheumatol Int. 2022. PMID: 34586472 Clinical Trial.
Secondary endpoints were improvement in DAS28, functional outcome and adverse events at 24 weeks. 136 eligible patients were randomized to either Leflunomide or Sulfasalazine group (68 in each group).63 and 59 patients in Leflunomide and 66 and 61 patients in Sulfas …
Secondary endpoints were improvement in DAS28, functional outcome and adverse events at 24 weeks. 136 eligible patients were randomized to e …
Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.
Zhang M, Qi C, Zha Y, Chen J, Luo P, Wang L, Sun Z, Wan J, Xing C, Wang S, Jiang G, Sun M, Chen Q, Chen J, Li D, Guan T, Ni Z. Zhang M, et al. Clin Rheumatol. 2019 Mar;38(3):859-867. doi: 10.1007/s10067-018-4348-z. Epub 2018 Nov 13. Clin Rheumatol. 2019. PMID: 30426311 Clinical Trial.
Leflunomide was given orally with a loading dose of 40 mg/day for 3 days followed by 20 mg/day. ...There were no statistically significant differences between groups in complete remission rate and partial remission rate. At week 24, 23% of patients in the leflunomide
Leflunomide was given orally with a loading dose of 40 mg/day for 3 days followed by 20 mg/day. ...There were no statistically signif
189 results